SVRA — Savara Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1160308 ·
Last close
$4.48
Market Cap
$988.39M
52W High
$7.01
52W Low
$4.13
ADV30
2,788,158
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -43,542,000 | -42,989,000 | 155,933,000 | 29,812,000 | 48,083,000 |
| Jun 2026 | 0 | — | -40,965,000 | -40,228,000 | 192,138,000 | 41,800,000 | 48,478,000 |
| Mar 2026 | 0 | — | -38,137,000 | -37,284,000 | 221,645,000 | 38,791,000 | 45,606,000 |
| Dec 2025 | 0 | — | -33,419,000 | -32,236,000 | 253,436,000 | 33,180,000 | 50,303,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-130,314,000
Investing CF
$8,825,000
Financing CF
$135,169,000
CapEx
$-631,000
Dividends Paid
—
Buybacks
$-5,434,000
EPS Diluted TTM
$-0.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-728,588,000
Inventory
—
Receivables
$1,117,000
ST Investments
$99,837,000
EBIT TTM
$-156,063,000
Pretax Income TTM
$-152,737,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,763,000 | -118,837,000 | 253,436,000 | 50,303,000 | 203,133,000 | -101,037,000 |
| Dec 2024 | 0 | -102,399,000 | -95,881,000 | 212,879,000 | 41,430,000 | 171,449,000 | -89,088,000 |
| Dec 2023 | 0 | -59,210,000 | -54,698,000 | 177,564,000 | 37,192,000 | 140,372,000 | -51,061,000 |
| Dec 2022 | 0 | -38,043,000 | -38,150,000 | 139,777,000 | 31,999,000 | 107,778,000 | -34,554,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-139,309,000
OpCashFlow TTM
—
Assets (Latest)
$192,138,000
Forward EPS
$-0.37
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $4.72 · call volume: 1,006 · put volume: 245
Expected Move to 2026-12-18:
±$2.17
(45.97%) —
implied range
$2.55 –
$6.89
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | $979.40M | $15.40 | — |
| ANRO | Alto Neuroscience, Inc. | $999.16M | $24.91 | — |
| CYRX | Cryoport, Inc. | $999.81M | $19.74 | — |
| SPTX | Seaport Therapeutics, Inc. | $972.65M | $18.17 | — |
| OMER | OMEROS CORP | $1.01B | $13.92 | — |
News headlines (Yahoo Finance, 1h cache)
FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
2026-11-16 10:09 · Yahoo
Savara Announces New Employment Inducement Grant
2026-11-12 21:05 · Yahoo
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
2026-10-21 17:10 · Yahoo
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
2026-10-13 08:14 · Yahoo
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
2026-10-12 20:05 · Yahoo
Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
2026-10-11 16:43 · Yahoo
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
2026-08-24 20:05 · Yahoo
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:05 · Yahoo
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
2026-07-30 12:05 · Yahoo
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 13:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.